

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
August 4, 2010
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 4, 2010.

2. Welcome

Debbie Tapley, RPh, called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Ed Behling, MD
Jody Bollinger, MD

Sara Lindsey, MD
Kelly Jones, PharmD

Debbie Tapley, RPh

SC DHHS:

Felicity Myers, PhD
James Assey, RPh
Deidra Singleton, JD
Vicki Johnson, JD
Valeria Williams

Magellan Medicaid Administration:

Bryan Amick, PharmD
Mary Roberts, RPh

Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 4, 2010.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. SC DHHS Presentation

Felicity Myers, Deputy Director of Medical Services, offered an overview of the budgetary challenges currently facing SC's Medicaid program. Fewer resources are available to provide services to a growing Medicaid population, and restrictions exist to prohibit DHHS from increasing eligibility threshold or decreasing provider reimbursement. These circumstances create an increasingly challenging budgetary condition, and the agency expects to run a deficit this year.

An overview of plans to expand the *Healthy Connections Choices* care coordination program was provided. Eligible populations will be required to receive care coordination through either a Medicaid Managed Care Organization (MCO) or the state's Medical Homes Network (MHN).

C. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

COMPANY	SPEAKER	DRUG
Shire US Inc	Christy Copeland, PharmD.	Lialda®
AstraZeneca	Sonja Grooms-Smith, PhD	Crestor®
Eli Lilly & Co.	Julie Kivior, BSN	Livalo®
Pfizer	William D. Yarbrough, MD	Lipitor®
Merck & Co.	Vicki L. Star, MD, FACR	Vytorin® Zetia®
Ortho-McNeil-Janssen Pharmaceuticals, Inc.	Anthony W. Alexander, MD	Nucynta®

D. Drug Classes for Review

Bryan Amick, Magellan Medicaid Administration, led the discussion for the following drug classes:

- Serotonin Receptor Agonists
- Statins
- Cholesterol Absorption Inhibitors
- Statin/Calcium Channel Blocker Combination Products
- Tramadol and Similar Analgesics
- Ulcerative Colitis Agents

The following are the recommendations of the P & T Committee:

<u>SEROTONIN RECEPTOR AGONISTS FOR MIGRAINE</u>	
<u>Preferred</u> SUMATRIPTAN	<u>Non-Preferred</u> AMERGE AXERT FROVA IMITREX MAXALT RELPAX TREXIMET ZOMIG
<u>STATINS</u>	
<u>Preferred</u> ALTOPREV CRESTOR LESCOL LESCOL XL LIPITOR LOVASTATIN PRAVASTATIN SIMVASTATIN	<u>Non-Preferred</u> LIVALO MEVACOR PRAVACHOL VYTORIN ZOCOR
<u>CHOLESTEROL REABSORPTIVE AGENTS</u>	
<u>Preferred</u> ZETIA	<u>Non-Preferred</u>

<u>STATIN/CCB COMBINATION PRODUCTS</u>	
<u>Preferred</u> CADUET	<u>Non-Preferred</u>
<u>TRAMADOL-LIKE AGENTS</u>	
<u>Preferred</u> TRAMADOL TRAMADOL/APAP	<u>Non-Preferred</u> NUCYNTA RYBIX RYZOLT ER TRAMADOL HCL SR ULTRACET ULTRAM ULTRAM ER
<u>ULCERATIVE COLITIS AGENTS</u>	
<u>Preferred</u> APRISO ASACOL BALSALAZIDE DISODIUM CANASA SUPP.RECT MESALAMINE ENEMA PENTASA SULFASALAZINE	<u>Non-Preferred</u> ASACOL HD AZULFIDINE COLAZAL DIPENTUM LIALDA MESALAMINE KIT ROWASA ENEMA KIT SFROWASA

5. Old Business

None

6. New Business

Committee members requested that we look at acute, short acting pain agents at our next P&T meeting. It was felt that NYCNTA® might be more appropriate for consideration within that group of medications.

Committee members were provided with instructions on completing the revised travel reimbursement forms.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS:

Serotonin Receptor Agonists
Statins
Cholesterol Absorption Inhibitors
Statin/Calcium Channel Blocker Combination Products
Tramadol and Similar Analgesics
Ulcerative Colitis Agents

8. Closing Comments

The next meeting will be held on Wednesday, November 3, 2010, at 4:00 PM at the same location.

9. Adjournment

The meeting adjourned at 5:02 PM.